Company Active LTD

Company profile

Freenome Limited

Freenome Limited is a UK company with status active founded in 2002 based in East Midlands.

CRN
04606727
Founded
2002
Age
23

Overview

Legal name
FREENOME LIMITED
Region
East Midlands
Registered address
MEDICITY - D6 BUILDING
1 THANE ROAD
NOTTINGHAM
UNITED KINGDOM
NG90 6BH
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

17 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

26 May
2026

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzUyMjY1MzYxMmFkaXF6a2N4 | Paper/PDF filed

Published 26 May 2026 22:44

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

03 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

12 Sep
2024

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzQzNTM3MzAxNWFkaXF6a2N4 | Paper/PDF filed

Published 13 Sep 2024 11:15

03 Dec
2002

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2020
Funded years
2020, 2021
Age at first award
17 years

Projects

2021 Collaborative R&D Lead participant

IMmunity Profiling of pAtients with Covid-19 for Therapy and Triage (IMPACTT)

1 Dec 2021 to 31 Jan 2022

Awarded
£84,333
Total cost £84,333

The IMPACTT project will study the immune profiles of 3,000 patients infected with SARS-CoV-2 in order to understand our immune responses to the virus. This project will generate five outputs: 1. Looking into patient immune profiles to better understand why some patients have very mild symptoms, yet other have severe reactions that result in ventilations ...

2020 Collaborative R&D Lead participant

IMmunity Profiling of pAtients with Covid-19 for Therapy and Triage (IMPACTT)

1 Oct 2020 to 31 Mar 2022

Awarded
£514,985
Total cost £643,732

The IMPACTT project will study the immune profiles of 3,000 patients infected with SARS-CoV-2 in order to understand our immune responses to the virus. This project will generate five outputs: 1\. Generation of a panel of immune related biomarkers that are predictive of response to treatment, including adverse events 2\. Understanding why some patients ha...

Product types

Collaborative R&D